| Literature DB >> 34926868 |
Diya Biju1, Soumya Johnson1, Chithra Valsan2, A B Prasad3, Praveenlal Kuttichira1.
Abstract
BACKGROUND: SARS CoV2 continues to pose a threat to human race even after one year of its outset in China. Observational studies from across the world have shown huge disparity in the clinicoepidemiological and laboratory features of this disease. In this study we attempt to assess the clinical, epidemiological and laboratory parameters of COVID 19 positive patients in this geographic location.Entities:
Keywords: COVID-19; Clinical characteristics; Coronavirus; India; Inflammatory markers; Kerala; Laboratory findings; Lymphocytopenia; Male vs female; SARS-CoV-2; Symptomatic vs asymptomatic
Year: 2021 PMID: 34926868 PMCID: PMC8666381 DOI: 10.1016/j.cegh.2021.100931
Source DB: PubMed Journal: Clin Epidemiol Glob Health ISSN: 2213-3984
Clinical and epidemiological characteristics of COVID-19 patients.
| Parameters | % | |
|---|---|---|
| AGE(YEAR) | ||
| 45.7 ± 18.68 | – | |
| 0–93 | – | |
| 37 | 3.52 | |
| 514 | 48.91 | |
| 295 | 28.07 | |
| ≥ | 205 | 19.50 |
| GENDER | ||
| 544 | 51.76 | |
| 507 | 48.24 | |
| PRESENCE OF SYMPTOMS | ||
| 658 | 62.61 | |
| 393 | 37.39 | |
| SIGNS AND SYMPTOMS | ||
| 458 | 43.58 | |
| 226 | 21.50 | |
| 167 | 15.89 | |
| 108 | 10.28 | |
| 105 | 9.99 | |
| 88 | 8.37 | |
| 65 | 6.18 | |
| 35 | 3.33 | |
| 31 | 2.95 | |
| 28 | 2.66 | |
| 19 | 1.81 | |
| 15 | 1.43 | |
Standard Deviation.
Laboratory findings of tested COVID-19 patients.
| Parameters | Total test done | % | |
|---|---|---|---|
| Leukocyte count (x109/L) | |||
| 483 | 383 | 79.3 | |
| 41 | 8.49 | ||
| 59 | 12.22 | ||
| Neutrophil count (%) | |||
| 481 | 327 | 67.98 | |
| 15 | 3.12 | ||
| 139 | 28.9 | ||
| Lymphocyte count (%) | |||
| 479 | 259 | 54.07 | |
| 165 | 34.45 | ||
| 55 | 11.48 | ||
| Eosinophil count (%) | |||
| 479 | 311 | 64.93 | |
| 158 | 32.99 | ||
| AST (U/L) | |||
| 436 | 203 | 46.56 | |
| 229 | 52.52 | ||
| ALT (U/L) | |||
| 449 | 319 | 71.05 | |
| 129 | 28.73 | ||
| ALP (U/L) | |||
| 396 | 350 | 88.38 | |
| 43 | 10.86 | ||
| Serum protein (g/dl) | |||
| 374 | 280 | 74.87 | |
| 84 | 22.46 | ||
| Potassium (meq/l) | |||
| 405 | 254 | 62.72 | |
| 143 | 35.31 | ||
| Sodium (meq/l) | |||
| 406 | 209 | 51.48 | |
| 194 | 47.78 | ||
| CRP (mg/dl) | |||
| 297 | 141 | 47.47 | |
| 155 | 52.19 | ||
| D-dimer (ng/ml) | |||
| 249 | 59 | 23.69 | |
| 48 | 19.28 | ||
| 142 | 57.03 | ||
| Ferritin (ng/ml) | |||
| 139 | 78 | 56.12 | |
| 58 | 41.73 | ||
| Troponin (ng/ml) | |||
| 42 | 19 | 45.24 | |
| 23 | 54.76 | ||
| LDH (U/L) | |||
| 31 | 10 | 32.26 | |
| 21 | 67.74 | ||
Aspartate Aminotransferase.
Alanine Aminotransferase.
Alkaline Phosphatase.
C Reactive Protein.
Lactate Dehydrogenase.
Comparison of symptomatic and asymptomatic COVID-19 patients.
| Variables | Total Case | Symptomatic | Asymptomatic | |
|---|---|---|---|---|
| Sex | .013 | |||
| Male | 544 | 360(66.2) | 184(33.8) | |
| Female | 507 | 298(58.8) | 209(41.2) | |
| Age(year) | .008 | |||
| Mean ± SD | 45.7 ± 18.6 | 47.2 ± 18.3 | 43.3 ± 19.01 | |
| Age≥64 year | 204 | 139(68.13) | 65(31.87) | |
| Laboratory parameter | ||||
| Increased D-dimer | 14 | 104(57.1) | 38(56.7) | 0.42 |
| Increased Ferritin | 58 | 45(43.7) | 13(36.1) | 0.27 |
| Increased Troponin | 23 | 18(51.4) | 5(71.4) | 0.32 |
| Increased LDH | 21 | 14(63.3) | 7(77.8) | 0.43 |
| Increased CRP | 155 | 122(58.7) | 33(37.1) | 0.001 |
| Leukocytopenia | 59 | 29(11.9) | 12(13) | 0.88 |
| Neutrophilia | 139 | 101(30.8) | 38(24.8) | 0.40 |
| Lymphocytopenia | 165 | 114(34.9) | 51(33.6) | 0.93 |
| Increased AST | 229 | 159(53.4) | 70(50.7) | 0.82 |
| Increased ALT | 129 | 92(30.2) | 37(25.7) | 0.41 |
| Increased ALP | 43 | 22(8.1) | 21(16.9) | 0.001 |
| Decreased Potassium | 143 | 106(38.4) | 37(28.7) | 0.053 |
| Decreased Sodium | 143 | 137(49.6) | 57(43.8 | 0.15 |
Lactate Dehydrogenase.
C Reactive Protein.
Aspartate Aminotransferase.
Alanine Aminotransferase.
Alkaline Phosphatase.
Comparison of male and female COVID-19 patients.
| Variables | Male n(%) | Female n(%) | |
|---|---|---|---|
| Mean age ± SD | 47.7 ± 18.3 | 43.7 ± 18.7 | .001 |
| Symptoms | |||
| 251(46.1) | 207(40.8) | .09 | |
| 134(24.6) | 92(18.1) | .01 | |
| 52(9.5) | 56(11.04) | .74 | |
| 45(11.8) | 60(8.3) | .06 | |
| 52(9.6) | 36(7.1) | .18 | |
| 28(5.1) | 37(7.3) | .14 | |
| Laboratory parameters | |||
| 35(13.7) | 24(10.6) | .52 | |
| 103(40.6) | 64(27.6) | .007 | |
| 85(33.3) | 54(23.9) | .71 | |
| 90(35.6) | 68(30.1) | .20 | |
| 94(57.3) | 61(45.9) | .07 | |
| 78(60.5) | 64(53.3) | .52 | |
| 47(54) | 11(21.2) | .001 | |
| 150(63.3) | 79(39.7) | .001 | |
| 92(37.6) | 37(18.1) | .001 | |
| 66(30.7) | 77(40.5) | .11 | |
| 123(56.4) | 71(37.8) | .001 | |
C Reactive Protein.
Aspartate Aminotransferase.
Alanine Aminotransferase.